Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies

Targeting the RAS pathway remains the holy grail of precision oncology. In the case of pancreatic ductal adenocarcinomas (PDAC), 90–92% harbor mutations in the oncogene KRAS, triggering canonical MAPK signaling. The smooth structure of the altered KRAS protein without a binding pocket and its affini...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy: Anna Linehan, Mary O’Reilly, Ray McDermott, Grainne M. O’Kane
Format: Artykuł
Język:English
Wydane: Frontiers Media S.A. 2024-03-01
Seria:Frontiers in Medicine
Hasła przedmiotowe:
KRAS
mutation
pancreatic cancer
tumor microenvironment
SHP2
metabolic impact
Dostęp online:https://www.frontiersin.org/articles/10.3389/fmed.2024.1369136/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2024.1369136/full

Podobne zapisy